These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 4070301)

  • 1. The National Cancer Institute's Drug Development Program.
    Schepartz SA
    Prog Clin Biol Res; 1985; 197():73-82. PubMed ID: 4070301
    [No Abstract]   [Full Text] [Related]  

  • 2. The National Institutes of Health Small Business Innovation Research (SBIR) Program: opportunities for orphan drug development.
    Engstrom LO
    Prog Clin Biol Res; 1985; 197():25-30. PubMed ID: 4070295
    [No Abstract]   [Full Text] [Related]  

  • 3. Orphan products development and some methods for maximizing the usefulness of research on rare diseases.
    Finkel MJ
    Prog Clin Biol Res; 1985; 197():11-8. PubMed ID: 4070285
    [No Abstract]   [Full Text] [Related]  

  • 4. The Antiepileptic Drug Development Program: an example of government-industry collaboration.
    White BG
    Prog Clin Biol Res; 1985; 197():83-93. PubMed ID: 4070302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Historical background of the National Cancer Institute's drug development thrust.
    Zubrod CG; Schepartz SA; Carter SK
    Natl Cancer Inst Monogr; 1977 Mar; (45):7-11. PubMed ID: 337156
    [No Abstract]   [Full Text] [Related]  

  • 6. NIH gives money for orphan development.
    Watanabe ME
    Nat Med; 2000 Nov; 6(11):1197-8. PubMed ID: 11062512
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of voluntary disease organizations in research and development of orphan drugs.
    Horansky R
    Prog Clin Biol Res; 1985; 197():179-81. PubMed ID: 4070293
    [No Abstract]   [Full Text] [Related]  

  • 8. The design and development of therapeutic agents for neuromuscular diseases.
    Lewis NJ
    Prog Clin Biol Res; 1985; 197():105-10. PubMed ID: 4070284
    [No Abstract]   [Full Text] [Related]  

  • 9. Orphan products activities of the National Institutes of Health.
    Schepartz SA
    Prog Clin Biol Res; 1983; 127():173-86. PubMed ID: 6889399
    [No Abstract]   [Full Text] [Related]  

  • 10. The US National Cancer Institute's natural products repository; origins and utility.
    Brown EC; Newman DJ
    J Environ Monit; 2006 Aug; 8(8):800-5. PubMed ID: 16896463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the National Cancer Institute in drug development.
    Doroshow J
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
    [No Abstract]   [Full Text] [Related]  

  • 12. The Orphan Products Board of the Department of Health & Human Services.
    Crooks GM
    Prog Clin Biol Res; 1985; 197():19-23. PubMed ID: 4070294
    [No Abstract]   [Full Text] [Related]  

  • 13. Strengthening commitment to clinical research: The National Heart, Lung, and Blood Institute's Specialized Centers of Research program.
    Lenfant C
    Circulation; 2002 Jan; 105(4):400-1. PubMed ID: 11815416
    [No Abstract]   [Full Text] [Related]  

  • 14. The perinatal research program of the National Institute of Child Health and Human Development.
    Hasselmeyer EG
    Clin Perinatol; 1976 Sep; 3(2):277-80. PubMed ID: 963921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Report of the Cancer Chemotherapy Collaborative Program Review Committee: the Richardson report. June 1966, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
    Cancer Treat Rep; 1984 Jan; 68(1):343-56. PubMed ID: 6692435
    [No Abstract]   [Full Text] [Related]  

  • 16. Developing drugs for developing countries.
    Ridley DB; Grabowski HG; Moe JL
    Health Aff (Millwood); 2006; 25(2):313-24. PubMed ID: 16522573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CMS move threatens to put orphan drugs out in cold.
    Carroll J
    Manag Care; 2003 Jul; 12(7):10-1. PubMed ID: 12891947
    [No Abstract]   [Full Text] [Related]  

  • 18. Perspectives. Orphan Drug Act stumps lawmakers.
    Firshein J
    Faulkner Grays Med Health; 1990 Jun; 44(25):suppl 4 p.. PubMed ID: 10105023
    [No Abstract]   [Full Text] [Related]  

  • 19. Contrasting viewpoints on cancer drug development: the Wooldridge and Richardson reports.
    DeVita VT
    Cancer Treat Rep; 1984 Jan; 68(1):339-40. PubMed ID: 6692433
    [No Abstract]   [Full Text] [Related]  

  • 20. Origins and development of chemotherapy research at the National Cancer Institute.
    Zubrod CG
    Cancer Treat Rep; 1984 Jan; 68(1):9-19. PubMed ID: 6362871
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.